PFA Pension Forsikringsaktieselskab Invests $10.91 Million in Insulet Corporation $PODD

Key Points

• PFA Pension purchased a new position of 37,992 Insulet shares valued at approximately $10.91 million, representing about 0.05% of the company.
• Insulet director Michael R. Minogue bought 2,030 shares at an average price of $246.23 (~$499,847), a 13.14% increase in his stake; insiders now own 0.36% of the stock.
• Insulet recently beat quarterly estimates with $1.55 EPS vs. $1.48 expected and revenue of $783.8M (up 31.2% YoY); analysts' consensus is a "Moderate Buy" with a $327.24 price target.

PFA Pension Forsikringsaktieselskab purchased a new position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 37,992 shares of the medical instruments supplier's stock, valued at approximately $10,905,000. PFA Pension Forsikringsaktieselskab owned approximately 0.05% of Insulet as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. Sage Mountain Advisors LLC raised its holdings in shares of Insulet by 4.6% during the 3rd quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier's stock worth $229,000 after buying an additional 33 shares in the last quarter. Glenmede Investment Management LP raised its holdings in shares of Insulet by 1.6% during the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier's stock worth $708,000 after buying an additional 35 shares in the last quarter. Curi Capital LLC raised its holdings in shares of Insulet by 0.8% during the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier's stock worth $1,365,000 after buying an additional 36 shares in the last quarter. WINTON GROUP Ltd raised its holdings in shares of Insulet by 0.9% during the 3rd quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier's stock worth $1,261,000 after buying an additional 37 shares in the last quarter. Finally, PDS Planning Inc raised its holdings in shares of Insulet by 5.1% during the 3rd quarter. PDS Planning Inc now owns 821 shares of the medical instruments supplier's stock worth $253,000 after buying an additional 40 shares in the last quarter.

Insider Activity at Insulet

In related news, Director Michael R. Minogue purchased 2,030 shares of Insulet stock in a transaction on Wednesday, February 25th. The shares were purchased at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the transaction, the director owned 17,483 shares of the company's stock, valued at approximately $4,304,839.09. This represents a 13.14% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.36% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on PODD shares. TD Cowen cut Insulet from a "buy" rating to a "hold" rating and set a $294.00 price target for the company. in a report on Monday, January 26th. Zacks Research cut Insulet from a "strong-buy" rating to a "hold" rating in a report on Monday, January 5th. Oppenheimer reduced their price objective on Insulet from $365.00 to $300.00 and set an "outperform" rating on the stock in a research report on Thursday, February 19th. Barclays restated an "underweight" rating and set a $286.00 price objective on shares of Insulet in a research report on Thursday, February 19th. Finally, Canaccord Genuity Group reduced their price objective on Insulet from $450.00 to $435.00 and set a "buy" rating on the stock in a research report on Wednesday, February 18th. Eighteen investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $327.24.

Insulet Stock Performance

NASDAQ PODD opened at $175.04 on Monday. The business's 50-day moving average price is $216.37 and its two-hundred day moving average price is $267.14. Insulet Corporation has a 12 month low of $158.35 and a 12 month high of $354.88. The firm has a market capitalization of $12.12 billion, a PE ratio of 50.01, a price-to-earnings-growth ratio of 1.03 and a beta of 1.20. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating analysts' consensus estimates of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm had revenue of $783.80 million for the quarter, compared to analyst estimates of $768.31 million. During the same quarter in the previous year, the company posted $1.15 EPS. The business's revenue was up 31.2% on a year-over-year basis. On average, analysts expect that Insulet Corporation will post 6.27 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.